Senactiv®

Panax notoginseng / Rosa roxburghii
Evidence Level
Moderate
2 Clinical Trials
4 Documented Benefits
3/5 Evidence Score

Senactiv® (formerly ActiGin®) is NuLiv Science's patented senolytic sportsceutical — a highly purified blend of Panax notoginseng and Rosa roxburghii extracts validated in 4 human clinical trials. It improves athletic performance through a novel triple mechanism: increasing mitochondrial energy production (47% more citrate synthase), accelerating glycogen resynthesis (370% faster), and clearing senescent muscle cells to allow new cell regeneration.

Studied Dose 50–100 mg/day; 50 mg is the established clinical dose
Active Compound Purified ginsenoside Rg1 (Panax notoginseng) + Rosa roxburghii fruit fractions — Senactiv® by NuLiv Science (50–100 mg/serving)

VO2 max and endurance improvement

Senactiv supplementation increased VO2 max time-to-exhaustion by 20% in a human HIIT cycling trial. Athletes sustained effort 20% longer and produced 20% more total work output vs. placebo — a performance improvement large enough to meaningfully impact competitive results.

Glycogen resynthesis acceleration

After a 60-minute cycling bout at 70% VO2 max, Senactiv supplementation increased muscle glycogen resynthesis rates by 370% (2.73x) over the 3 hours post-exercise vs. placebo. Faster glycogen restoration means faster recovery and ability to train again sooner.

Citrate synthase and ATP production

Muscle biopsies from Senactiv subjects showed 47% more citrate synthase enzyme activity — the rate-limiting enzyme of the Krebs cycle and the primary determinant of aerobic ATP production capacity. More citrate synthase means more efficient energy generation during sustained effort.

Senescent cell clearance

In a HIIT cycling study, 9 of 12 Senactiv subjects showed complete elimination of senescent muscle cells (marked by β-galactosidase) after exercise — vs. no change in placebo. Clearing old dysfunctional cells allows healthier, more mitochondria-rich new cells to populate muscle tissue.

1

Ginsenoside Rg1 anti-inflammatory and mitochondrial signaling

The ginsenoside Rg1 from Panax notoginseng reduces exercise-induced inflammatory signaling in skeletal muscle (TNF-α, IL-6, lipid peroxidation), while simultaneously promoting citrate synthase expression and mitochondrial biogenesis — improving the energy production efficiency of active muscle tissue.

2

Insulin receptor and GLUT4 preservation during exercise

Intense exercise disrupts insulin receptor and GLUT4 transporter function in muscle membranes, slowing glucose uptake and glycogen replenishment. Senactiv preserves GLUT4 expression and insulin receptor integrity during HIIT, maintaining the glucose supply pipeline for faster glycogen restoration post-exercise.

3

Senolytic clearance of β-galactosidase-positive cells

Senactiv activates macrophage infiltration of exercised muscle tissue, which selectively identifies and removes senescent cells marked by β-galactosidase accumulation. This cellular 'housekeeping' effect allows muscle stem cells to generate fresh, high-performance muscle cells in their place.

1
ActiGin/Senactiv and HIIT Performance — Human RCT
PubMed

Randomized, double-blind, placebo-controlled crossover study in healthy young men performing HIIT cycling. Measured VO2 max time-to-exhaustion, citrate synthase activity, and glycogen levels via muscle biopsy.

Healthy young men. Crossover HIIT cycling protocol.

Senactiv group: 20% longer time-to-exhaustion at VO2 max, 47% higher citrate synthase activity in muscle biopsy, significantly reduced lipid peroxidation and inflammatory markers vs. placebo. Published in PLoS One, 2015.

2
Senactiv and Senescent Cell Clearance in Exercising Humans
PubMed

RDBPC crossover study examining senolytic effects of Senactiv in 12 young men performing HIIT cycling, with muscle biopsies analyzed for β-galactosidase-positive senescent cells.

12 healthy young men. HIIT crossover protocol with muscle biopsy.

9 of 12 Senactiv subjects showed complete elimination of senescent cells post-exercise vs. no changes in placebo group. First human demonstration of exercise-induced senescent cell clearance by a nutritional ingredient. Published in Aging journal.

Common Potential side effects

No known side effects at the 50 mg clinical dose
GRAS affirmed and Informed Ingredient certified since 2016
Generally recognized as extremely safe across all published human trials

Important Drug interactions

Anticoagulants — Panax notoginseng traditionally used for circulation; potential mild platelet effects; monitor with warfarin
Immunosuppressants — ginseng compounds may modulate immune activity; caution in transplant patients
No established drug interactions at standard 50–100 mg doses